IBRX
ImmunityBio, Inc. - Common Stock - Recent news and sentiment analysis
Default charts cover the last 24 hours by "day" period and sentiment shares compare positive vs. negative mentions after removing neutral posts.
Price
Today
Users
Total
IBRX Price & Sentiment Over Time
Sentiment series exclude neutral posts so the green/red balance matches the bar on the home page; price points use the latest available quote.
IBRX
Ibrx twitching a bit
IBRX
NVDA,ZETA,IBRX
Shkreli is an absolute mad lad fucking with biotechs. Some of those companies swing like the meme co...
Shkreli is an absolute mad lad fucking with biotechs. Some of those companies swing like the meme coins of old. I swore off them after IBRX a year ago. Not really surprised.
$IBRX DD — Why I think it has strong potential
TLDR: $IBRX is a commercial biotech with an FDA approved bladder cancer immunotherapy (ANKTIVA) and revenues are ramping. Position: 300 shares @ 2.32 1) What is IBRX? ImmunityBio is an immuno-oncology company. Their main product: - ANKTIVA (nogapendekin alfa inbakicept-pmln) FDA approved use: - ANKTIVA with BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with CIS ± papillary tumors. ——— 2) Why I think the product is legit Reported long-term results from QUILT-3.032 coverage: - 71% complete response (CR) - 84% cystectomy-free at 36 months among responders - Reported disease-specific overall survival ~99% at 36 months The bull angle: durability builds physician confidence and can drive adoption. ——— 3) The real bull case: revenue is ramping (not just hype) This is what changes it from story to business: - Q3 2025 product revenue: ~$31.8M - Other earnings summaries show ~$32.06M Q3 revenue and losses improving YoY (still a loss, but trending). If they keep stacking quarters like this, the market can revalue this company quickly. ——— 4) Shorts are crowded (this is the extra fuel) Short interest is objectively large: - 81.06M shares short - Short % of float ~24–27% (varies by source) If positive news brings heavy buying volume, shorts can be forced to cover into strength. Note: borrow cost looks low recently, so this is more a catalyst movement than shorts trapped by borrow fees. ——— 5) What could send it higher - Another quarter of strong sales growth / better commentary - Label expansion / regulatory progress (bigger market = bigger story) - Reimbursement / guideline momentum - Partnership or other credibility event ——— 6) Risks - Ramp slows (adoption doesn’t scale) - Dilution (biotech classic) - Execution problems (commercial rollout is hard) - Single product concentration (ANKTIVA is the story) ——— Bottom line I’m bullish because it’s a rare combo of: - FDA approved product in a real unmet-need cancer setting - Strong reported durability data - Real revenue ramp - Crowded short positioning as potential upside fuel Not financial advice. Do your own DD.
Nice to see 😊 Ibrx move
Ibrx
$IBRX
Listen if you guys want to squeeze u need to do the 5 min rule. $IBRX
Listen if you guys want to squeeze u need to do the 5 min rule. $IBRX
my IBRX leaps collecting dust c'mon DO SOMETHING
my IBRX leaps collecting dust c'mon DO SOMETHING
$IBRX could be the next short squeeze with 70% shorted.
$IBRX could be the next short squeeze with 70% shorted.
$ibrx
TMC (the metals company going after deep sea minerals valued at $23.6B) BBAI (mini-palantir) IBRX ...
TMC (the metals company going after deep sea minerals valued at $23.6B) BBAI (mini-palantir) IBRX (oncology w/pipeline, efficacyx100 w/surprising results) MELI (South American oversold “Amazon”)
TCM (the metals company) vessel’s completed sampling found $23.6B in minerals deep sea drilling, nex...
TCM (the metals company) vessel’s completed sampling found $23.6B in minerals deep sea drilling, next stop … drill baby drill!!! IBRX small profitable oncology pipeline entering expedited Phase 3 trials after thru the roof phase 2 efficacy …. Big possibilities with limited downside! YYAI - bought yesterday and ridiculously 80% oversold shedding new company shares, bottomed today and climbed back 8% by close with way more to make up! I am holding shares in all 3 …. G’luck all :)
IBRX 🚀🚀🚀🚀🚀